XML 26 R27.htm IDEA: XBRL DOCUMENT v3.20.1
Stock-Based Compensation (Tables)
 3 Months Ended
Mar. 31, 2020
Share-based Payment Arrangement [Abstract]  
Schedule of Valuation Assumptions For performance-based restricted stock units granted during the three months ended March 31, 2020 valued using the Monte Carlo Simulation valuation model, we used the following assumptions:
 Three Months EndedThree Months Ended
 March 31, 2020March 31, 2019
Risk-free interest rate1.16 %2.48 %
Expected dividend yield— %— %
Term3 years3 years
Expected volatility40.0 %45.0 %
Weighted-average expected volatility40.0 %45.0 %
Schedule of Stock Option Activity and Weighted Average Exercise Prices
The following table summarizes stock option activity and weighted-average exercise prices during the three months ended March 31, 2020:
OptionsWeighted-
Average
Exercise Price		Weighted-Average
Remaining
Contractual Term
(Years)		Aggregate Intrinsic
Value as of
March 31, 2020
Outstanding at January 1, 2020486,682  $52.37  
Granted—  —  
Forfeited or expired(9,740) 50.74  
Exercised(57,180) 39.18  
Outstanding at March 31, 2020419,762  $54.20  3.2$1,000  
Options exercisable at March 31, 2020408,489  $54.00  2.0$1,000  
Schedule of Restricted Stock and Restricted Stock Units Activity and Weighted-Average Grant Date Fair Value
The following table summarizes the restricted stock and restricted stock unit activity and weighted average grant-date fair values for the three months ended March 31, 2020:
SharesWeighted-Average
Grant Date
Fair Value
Non-vested at January 1, 2020398,318  $49.53  
Granted167,161  66.77  
Forfeited(16,449) 48.67  
Vested(125,399) 39.16  
Non-vested at March 31, 2020423,631  $59.44  
Share-based Payment Arrangement, Expensed and Capitalized, Amount
The following table summarizes total stock-based compensation expense for each of the line items on our condensed consolidated statement of operations:
Three Months Ended
March 31, 2020March 31, 2019
Cost of Sales
Product$154  $153  
Service117  80  
Total cost of sales$271  $233  
Operating Expenses
Selling, general and administrative$1,523  $2,134  
Research and development382  197  
Total operating expenses$1,905  $2,331